COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02264574




Registration number
NCT02264574
Ethics application status
Date submitted
1/10/2014
Date registered
15/10/2014
Date last updated
21/09/2020

Titles & IDs
Public title
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Scientific title
A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Secondary ID [1] 0 0
PCYC-1130-CA
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Lymphocytic Leukemia 0 0
Small-Cell Lymphoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ibrutinib
Treatment: Drugs - Obinutuzumab
Treatment: Drugs - Chlorambucil

Experimental: IBR + OB - Ibrutinib (IBR) given orally at a dose of 420 mg/day until progressive disease or unacceptable toxicity. Intravenous obinutuzumab (OB) given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until progressive disease or unacceptable toxicity.

Experimental: CLB + OB - Chlorambucil (CLB) given orally at a dose of 0.5 mg/kg body weight up to a total of 6 cycles on Days 1 and 15 of each cycle or until disease progression or unacceptable toxicity.
Intravenous obinutuzumab given on Days 1 and 2 (100 mg on Day 1 and 900 mg on Day 2), 1000 mg on Days 8 and 15 of Cycle 1 and 1000 mg on Day 1 of each cycle up to 6 cycles or until disease progression or unacceptable toxicity.


Treatment: Drugs: Ibrutinib
Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.

Treatment: Drugs: Obinutuzumab
Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration

Treatment: Drugs: Chlorambucil
Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30 - PFS was defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.
The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented.
Timepoint [1] 0 0
Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Primary outcome [2] 0 0
Final Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48 - PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.
As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented.
Timepoint [2] 0 0
Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Secondary outcome [1] 0 0
Primary Analysis: PFS in High-Risk Sub-Population (del17p/TP53 Mutation/Del 11q) Based on IRC Assessment - Kaplan Meier Landmark Estimates at Month 30 - PFS was analyzed within the high-risk sub-population of participants with del17p or TP53 mutation or del 11q at baseline per central lab results. PFS was defined as time from the date randomization to the date of first IRC-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease.
As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented.
Timepoint [1] 0 0
Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Secondary outcome [2] 0 0
Primary Analysis: Rate of Sustained Hemoglobin Improvement - Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase = 2 g/dL over baseline continuously for = 56 days without blood transfusions or growth factors.
Timepoint [2] 0 0
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Secondary outcome [3] 0 0
Primary Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response - Percentage of participants who achieved MRD-negative response, defined as < 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders.
Timepoint [3] 0 0
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Secondary outcome [4] 0 0
Primary Analysis: Overall Response Rate (ORR) Based on IRC Assessment - ORR, defined as the percentage of participants achieving a best overall response of protocol-specified complete response (CR), CR with incomplete blood count recovery (CRi), nodular partial response (nPR), or partial response (PR) per IRC assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate.
Timepoint [4] 0 0
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Secondary outcome [5] 0 0
Primary Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 30 - OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive.
As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier landmark estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 30 [primary analysis]) are presented.
Timepoint [5] 0 0
Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]).
Secondary outcome [6] 0 0
Primary Analysis: Rate of Grade = 3 or Serious Infusion-Related Reaction (IRR) Adverse Events - Percentage of participants experiencing grade = 3 (severe or life threatening) or serious IRR adverse events that started on the day of an obinutuzumab infusion and were assessed as related or possibly related to obinutuzumab. Categories included those events with the Medical Dictionary for Regulatory Activities (MedDRA) dictionary preferred term of IRR and those events which are among the customized standardized MedDRA query (SMQ) for IRR.
Timepoint [6] 0 0
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Secondary outcome [7] 0 0
Primary Analysis: Rate of Sustained Platelet Improvement - Percentage of participants with platelet counts increase = 50% over baseline continuously for = 56 days without blood transfusion or growth factors.
Timepoint [7] 0 0
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Secondary outcome [8] 0 0
Primary Analysis: Rate of Clinically Meaningful Improvement in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire EuroQol Five-Dimension (EQ-5D-5L) - Percentage of participants with EQ-5D-5L utility score increase = 0.08 points over baseline at or prior to initiation of subsequent antineoplastic therapy. The EQ-5D-5L is a standardized non-disease specific instrument for describing and valuing health-related quality of life, comprising 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. A unique EQ-5D-5L health state is defined by combining the numeric level scores for each of the 5 dimensions and the total score is normalized from -0.594 to 1.000, with higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. Participants with missing EQ-5D-5L data were considered not achieving clinically meaningful improvement.
Timepoint [8] 0 0
Median follow-up time was 31.3 months at the time of the primary analysis (data cutoff date: 26 March 2018).
Secondary outcome [9] 0 0
Final Analysis: PFS in High-Risk Population (del17p/TP53 Mutation/Del 11q/Unmutated Immunoglobulin Heavy Chain Variable Region [IGHV]) Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48 - PFS was analyzed within the high-risk population of participants with del17p or TP53 mutation or del 11q or IGHV unmutated at baseline per central lab results. PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the IWCLL 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of PD was not considered progressive disease.
As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented.
Timepoint [9] 0 0
Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Secondary outcome [10] 0 0
Final Analysis: Rate of Sustained Hemoglobin Improvement - Percentage of participants with sustained hemoglobin improvement, defined as hemoglobin increase = 2 g/dL over baseline continuously for = 56 days without blood transfusions or growth factors.
Timepoint [10] 0 0
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Secondary outcome [11] 0 0
Final Analysis: Rate of Minimal Residual Disease (MRD)-Negative Response - Percentage of participants who achieved MRD-negative response, defined as < 1 CLL cell per 10,000 leukocytes as assessed by flow cytometry of a bone marrow aspirate per central laboratory. MRD samples were collected before initiation of subsequent antineoplastic treatment and MRD status was reported by central lab within 5 days after collection date. Participants with missing MRD data were considered non-responders.
Timepoint [11] 0 0
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Secondary outcome [12] 0 0
Final Analysis: ORR Based on Investigator Assessment - ORR, defined as the percentage of participants achieving a best overall response of protocol-specified CR, CRi, nPR or PR per investigator assessment at or prior to initiation of subsequent antineoplastic therapy. Assessment of response included physical examination, radiographic imaging, and evaluation of blood and marrow (if applicable), evaluated in accordance with the IWCLL 2008 criteria (Halleck et al). CR, CRi, nPR, and PR required confirmation with 2 consecutive assessments that were at least 56 days apart and no use of blood supportive product and/or growth factor during this period. Kaplan-Meier estimate.
Timepoint [12] 0 0
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).
Secondary outcome [13] 0 0
Final Analysis: Overall Survival (OS) - Kaplan Meier Landmark Estimates at Month 48 - OS, defined as the time from the date of randomization to the date of death from any cause. All deaths observed as the time of the analysis were considered as events. For participants who were not known to have died at the time of the analysis, OS data were censored at the date last known alive.
As the median OS was not reached in either treatment arm at the time of the analysis, Kaplan Meier point estimates of the OS rate (that is, the estimated percentage of participants still surviving at Month 48 [final analysis]) are presented.
Timepoint [13] 0 0
Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]).
Secondary outcome [14] 0 0
Final Analysis: Rate of Sustained Platelet Improvement - Percentage of participants with platelet counts increase = 50% over baseline continuously for = 56 days without blood transfusion or growth factors.
Timepoint [14] 0 0
Median follow-up time was 44.6 months at the time of the final analysis (data cutoff date: 17 October 2019).

Eligibility
Key inclusion criteria
Disease Related:

1. Diagnosis of CLL/SLL that meets IWCLL diagnostic criteria.

2. Age 65 yrs and older OR if less than 65 years, must have at least one of the following
criteria:

- Cumulative Illness Rating Score (CIRS) >6

- Creatinine clearance estimated <70 mL/min using Cockcroft-Gault equation.

- Del 17p by fluorescence in situ hybridization (FISH) or TP53 mutation by
polymerase chain reaction (PCR) or Next Generation Sequencing

3. Active disease meeting at least 1 of the following IWCLL criteria for requiring
treatment:

- Evidence of progressive marrow failure as manifested by the development of, or
worsening of, anemia and thrombocytopenia

- Massive, progressive, or symptomatic splenomegaly

- Massive nodes (at least 10 cm longest diameter), or progressive or symptomatic
lymphadenopathy.

- Progressive lymphocytosis with an increase of more than 50 percent over a 2-month
period or a lymphocyte doubling time (LDT) of <6 months. LDT may be obtained by
linear regression extrapolation of absolute lymphocyte counts obtained at
intervals of 2 weeks over an observation period of 2 to 3 months. In patients
with initial blood lymphocyte counts of <30,000/µL, LDT should not be used as a
single parameter to define indication for treatment. In addition, factors
contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infections)
should be excluded.

- Autoimmune hemolytic anemia and/or immune thrombocytopenia that is poorly
responsive to corticosteroids or other standard therapy.

- Autoimmune hemolytic anemia is defined by at least one marker of hemolysis
(indirect bilirubin above the upper limit of normal (ULN) not due to liver
disease, increased lactate dehydrogenase (above ULN) without alternative
etiology, or increased absolute reticulocytosis (above ULN) or bone marrow
erythropoiesis in the absence of bleeding AND at least one marker direct or
indirect autoimmune mechanism (positive direct antiglobulin for immunoglobulin G
[IgG] or C3d, cold agglutinins).

- Immune thrombocytopenia is defined by platelets =100,000/µL and increased
megakaryocytes on the bone marrow exam.

- Constitutional symptoms, defined as one or more of the following disease-related
symptoms or signs, documented in the patient's record prior to randomization:

- unintentional weight loss >10 percent within 6 months prior to screening.

- significant fatigue (inability to work or perform usual activities).

- fevers >100.5°F or 38.0°C for 2 or more weeks prior to screening without evidence
of infection.

- night sweats for more than 1 month prior to screening without evidence of
infection.

4. Measurable nodal disease by computed tomography (CT), defined as at least 1 lymph node
>1.5 cm in the longest diameter in a site that has not been previously irradiated. An
irradiated lesion may be assessed for measurable disease only if there has been
documented progression in that lesion since radiotherapy has ended.

Laboratory

5. Adequate hematologic function independent of transfusion and growth factor support for
at least 7 days prior to screening and randomization.

6. Adequate hepatic and renal function

7. Men and women = 18 years of age.

8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Any prior treatment of CLL or SLL

2. Evidence of central nervous system (CNS) involvement with primary disease of CLL/SLL

3. History of other malignancies, except:

- Malignancy treated with curative intent and with no known active disease present
for =3 years before the first dose of study drug and felt to be at low risk for
recurrence by treating physician.

4. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura

5. Known or suspected history of Richter's transformation.

6. Concurrent administration of >20mg/day of prednisone within 7 days of randomization
unless indicated for prophylaxis or management of allergic reactions (eg, contrast)

7. Known hypersensitivity to one or more study drugs

8. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.

9. Any uncontrolled active systemic infection or an infection requiring systemic
treatment that was completed = 7 days before randomization.

10. Known bleeding disorders or hemophilia.

11. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

12. Known history of human immunodeficiency virus (HIV) or active with hepatitis B virus
(HBV) or hepatitis C virus (HCV).

13. Major surgery within 4 weeks of randomization.

14. Any life-threatening illness, medical condition, or organ system dysfunction that, in
the investigator's opinion, could compromise the subject's safety or put the study
outcomes at undue risk.

15. Currently active, clinically significant cardiovascular disease, such as uncontrolled
arrhythmia or Class 3 or 4 congestive heart failure or a history of myocardial
infarction, unstable angina, or acute coronary syndrome within 6 months prior to
randomization.

16. Unable to swallow capsules or malabsorption syndrome, disease significantly affecting
gastrointestinal function, or resection of the stomach or small bowel, symptomatic
inflammatory bowel disease or ulcerative colitis, or partial or complete bowel
obstruction.

17. Concomitant use of warfarin or other vitamin K antagonists.

18. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor.

19. Lactating or pregnant

20. Unwilling or unable to participate in all required study evaluations and procedures.

21. Unable to understand the purpose and risks of the study and to provide a signed and
dated informed consent form (ICF) and authorization to use protected health
information (in accordance with national and local subject privacy regulations).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD,SA,VIC
Recruitment hospital [1] 0 0
Site Reference ID/Investigator #0503 - Woolloongabba
Recruitment hospital [2] 0 0
Site Reference ID/Investigator# 0650 - Adelaide
Recruitment hospital [3] 0 0
Site Reference ID/Investigator# 0888 - Ballarat
Recruitment hospital [4] 0 0
Site Reference ID/Investigator# 0193 - Box Hill
Recruitment hospital [5] 0 0
Site Reference ID/Investigator# 0633 - Fitzroy
Recruitment hospital [6] 0 0
Site Reference ID/Investigator# 0170 - Heidelberg
Recruitment postcode(s) [1] 0 0
- Woolloongabba
Recruitment postcode(s) [2] 0 0
- Adelaide
Recruitment postcode(s) [3] 0 0
- Ballarat
Recruitment postcode(s) [4] 0 0
- Box Hill
Recruitment postcode(s) [5] 0 0
- Fitzroy
Recruitment postcode(s) [6] 0 0
- Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Kentucky
Country [4] 0 0
United States of America
State/province [4] 0 0
Nevada
Country [5] 0 0
United States of America
State/province [5] 0 0
Ohio
Country [6] 0 0
United States of America
State/province [6] 0 0
Tennessee
Country [7] 0 0
Austria
State/province [7] 0 0
Linz
Country [8] 0 0
Austria
State/province [8] 0 0
Salzburg
Country [9] 0 0
Belgium
State/province [9] 0 0
Leuven
Country [10] 0 0
Belgium
State/province [10] 0 0
Turnhout
Country [11] 0 0
Canada
State/province [11] 0 0
Alberta
Country [12] 0 0
Czechia
State/province [12] 0 0
Hradec Kralove
Country [13] 0 0
Czechia
State/province [13] 0 0
Praha 10
Country [14] 0 0
France
State/province [14] 0 0
Gironde
Country [15] 0 0
France
State/province [15] 0 0
Loire Atlantique
Country [16] 0 0
France
State/province [16] 0 0
Meurthe Et Moselle
Country [17] 0 0
France
State/province [17] 0 0
Pyrenees Atlantiques
Country [18] 0 0
Israel
State/province [18] 0 0
Haifa
Country [19] 0 0
Israel
State/province [19] 0 0
Jerusalem
Country [20] 0 0
Israel
State/province [20] 0 0
Petach Tikva
Country [21] 0 0
Israel
State/province [21] 0 0
Tel Aviv
Country [22] 0 0
Israel
State/province [22] 0 0
Zerifin
Country [23] 0 0
Italy
State/province [23] 0 0
Firenze
Country [24] 0 0
Italy
State/province [24] 0 0
Milano
Country [25] 0 0
Italy
State/province [25] 0 0
Modena
Country [26] 0 0
Italy
State/province [26] 0 0
Novara
Country [27] 0 0
Italy
State/province [27] 0 0
Roma
Country [28] 0 0
Italy
State/province [28] 0 0
Siena
Country [29] 0 0
New Zealand
State/province [29] 0 0
Auckland
Country [30] 0 0
New Zealand
State/province [30] 0 0
Hamilton
Country [31] 0 0
Poland
State/province [31] 0 0
Brzozow
Country [32] 0 0
Poland
State/province [32] 0 0
Lodz
Country [33] 0 0
Russian Federation
State/province [33] 0 0
Nizhniy Novgorod
Country [34] 0 0
Russian Federation
State/province [34] 0 0
Ryazan
Country [35] 0 0
Russian Federation
State/province [35] 0 0
Saint-Petersburg
Country [36] 0 0
Russian Federation
State/province [36] 0 0
St. Petersburg
Country [37] 0 0
Russian Federation
State/province [37] 0 0
Yaroslavl
Country [38] 0 0
Spain
State/province [38] 0 0
Madrid
Country [39] 0 0
Spain
State/province [39] 0 0
Barcelona
Country [40] 0 0
Spain
State/province [40] 0 0
Salamanca
Country [41] 0 0
Sweden
State/province [41] 0 0
Borås
Country [42] 0 0
Sweden
State/province [42] 0 0
Luleå
Country [43] 0 0
Sweden
State/province [43] 0 0
Lund
Country [44] 0 0
Sweden
State/province [44] 0 0
Stockholm
Country [45] 0 0
Turkey
State/province [45] 0 0
Nisantasi
Country [46] 0 0
Turkey
State/province [46] 0 0
Ankara
Country [47] 0 0
Turkey
State/province [47] 0 0
Denizli
Country [48] 0 0
Turkey
State/province [48] 0 0
Izmir
Country [49] 0 0
Turkey
State/province [49] 0 0
Samsun
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Essex
Country [51] 0 0
United Kingdom
State/province [51] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Pharmacyclics LLC.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to evaluate the efficacy of ibrutinib in combination
with obinutuzumab compared to chlorambucil in combination with obinutuzumab based on the
Independent Review Committee (IRC) assessment of progression free survival (PFS). Efficacy
will be evaluated according to 2008 International Workshop for Chronic Lymphocytic Leukemia
(IWCLL) criteria with the modification for treatment-related lymphocytosis, in subjects with
treatment-naive CLL or SLL.
Trial website
https://clinicaltrials.gov/show/NCT02264574
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Lori Styles
Address 0 0
Pharmacyclics LLC.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications